Description
Price: $23.21 - $15.98
(as of Jul 06, 2024 12:45:16 UTC – Details)
Abreva 10% Docosanol helps shorten healing time of cold sores (1). Formulated with 10% docosanol, this fever blister and cold sore medication helps to shorten the duration of tingling, pain, burning and itching associated with cold sores if used as directed at the first sign of a tingle. Abreva Cold Sore Treatment penetrates deep (2) to create a barrier around healthy skin cells to prevent the spread of herpes simplex virus type 1 (HSV-1). Abreva Cold Sore lip treatment is a nonprescription cold sore medicine that shortens healing time to heal cold sores in as few as 2.5 days (1). This cream should be applied 5 times a day until your cold sore is fully healed, for a maximum of 10 days. This Abreva 10 Percent Docosanol pump bottle is easy to apply and take on the go for whenever you need a cold sore treatment for lips. (1) When used at the first sign median healing time is 4.1 days, 25 percent of users healed in 2.5 days (2) Based on laboratory data (3) Among OTC cold sore treatments, when used at the first sign
Is Discontinued By Manufacturer : No
Product Dimensions : 5.45 x 5 x 1.6 inches; 1 ounces
Item model number : 80155
Date First Available : September 9, 2000
Manufacturer : GlaxoSmithKline
ASIN : B000UALM1G
Can Heal in 2.5 Days: Fever blister smooth, white cream contains 10% docosanol to shorten the duration of cold sore symptoms (1) by blocking the virus from infecting healthy cells
Nothing Heals Fever Blisters Faster: Scientifically-proven medicine to shorten cold sore healing time
Lip Cream Clinically Proven to Shorten Duration of Symptoms: Cold sore product shortens duration of tingling, pain, burning and itching associated with cold sores (1)
Portable Cold Sore Cream: Packaged in a convenient pump bottle for on the go cold sore treatment
Number 1 Dermatologist Recommended Cold Sore Treatment: Abreva Cream is a nonprescription cold sore medicine that shortens healing time (1)
HSA and FSA eligible product
Reviews
There are no reviews yet.